Cargando…

Pro Re Nata Prescription and Perception Difference between Doctors and Nurses

BACKGROUND: Pro re nata (PRN) prescription is a frequently used prescription method in hospitals. This study was conducted to investigate actual condition of PRN prescription and whether administration error occurred because of perception difference between doctors and nurses. METHODS: From May to J...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Se Hwa, Woo, Ji Eun, Lee, Dong Woo, Choi, Won Cheol, Yoon, Jong Lull, Kim, Mee Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Family Medicine 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129247/ https://www.ncbi.nlm.nih.gov/pubmed/25120891 http://dx.doi.org/10.4082/kjfm.2014.35.4.199

Ejemplares similares

Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review
por: Vaismoradi, Mojtaba, et al.
Publicado: (2018)

Pro Re Nata Use of Psychotropic Medications in Assisted Living
por: Carder, Paula, et al.
Publicado: (2020)

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Influence of Psychotropic Pro Re Nata Drug Use on Outcomes in Hospitalized Patients with Schizophrenia
por: Kyou, Yoshitaka, et al.
Publicado: (2023)

The use and effectiveness of pro re nata psychotropic medications in children and adolescents: A systematic review
por: Asogwa, Kenneth, et al.
Publicado: (2017)

The monitoring and use of Pro re nata (PRN) psychotropic medication for people with learning disabilities on an inpatient ward
por: Mistry, Heena
Publicado: (2021)

Potentially Inappropriate Medication Use among Nursing Home Residents: Medication Errors Associated with Pro re nata Medications and the Importance of Pill Burden
por: Koçak, Fatma Özge Kayhan, et al.
Publicado: (2022)

Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion
por: Unsal, Erkan, et al.
Publicado: (2015)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol
por: Lin, Tiezhu, et al.
Publicado: (2020)

Audit on use of PRN (pro re nata) psychotropic medication for behavioural disturbance in individuals with intellectual disability in the community
por: Dhandapani, Asha, et al.
Publicado: (2021)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto, Akiko, et al.
Publicado: (2013)

Real-world experience with pro re nata dosing of intravitreal dexamethasone implant for eyes with refractory diabetic macular edema
por: Rishi, Pukhraj, et al.
Publicado: (2020)

Older Adults Living in Sheltered Housing’s Experiences of Involvement in Pro Re Nata Decisions. A Narrative Positioning Analysis
por: Nilsen, Marianne Kollerøs, et al.
Publicado: (2021)

Use of Psychotropic “Pro Re Nata” Medications by Patients Attending the Outpatient Clinic in a Hospital: A Qualitative Exploration
por: Rajiah, Kingston, et al.
Publicado: (2021)

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
por: Takamura, Yoshihiro, et al.
Publicado: (2021)

Does accreditation improve pro re nata benzodiazepines administration in psychiatric inpatients? Pre-post accreditation medical record comparison
por: Al-Sughayir, Mohammed Abdullah
Publicado: (2017)

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
por: Jia, Huixun, et al.
Publicado: (2022)

The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the “Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)” project
por: Kyou, Yoshitaka, et al.
Publicado: (2022)

‘To give or not to give medication, that is the question.’ Healthcare personnel’s perceptions of factors affecting pro re nata medication in sheltered housing for older adults — a focus-group interview study
por: Nilsen, Marianne Kollerøs, et al.
Publicado: (2020)

Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
por: Inoue, Maiko, et al.
Publicado: (2014)

Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV
por: Wecker, Thomas, et al.
Publicado: (2017)

Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
por: Lai, Tso-Ting, et al.
Publicado: (2022)

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
por: Victor, Andi Arus, et al.
Publicado: (2022)

Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
por: Narayanan, Raja, et al.
Publicado: (2016)

Pro re nata prescribing and administration for neuropsychiatric symptoms and pain in long-term care residents with dementia and memory problems: a cross-sectional study
por: Griffiths, Alys W., et al.
Publicado: (2019)

Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial
por: Yoon, Chang Ki, et al.
Publicado: (2022)

Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen
por: Miere, Alexandra, et al.
Publicado: (2018)

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
por: Elwes, Flora, et al.
Publicado: (2018)

Abstracts of the 2022 48th Annual NATAS Conference
por: Adams, Tina, et al.
Publicado: (2022)

Abstracts of the 2023 49th Annual NATAS Conference
por: LaVan, David, et al.
Publicado: (2023)

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration
por: Aurell, Sandra, et al.
Publicado: (2018)

One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
por: Wang, Fenghua, et al.
Publicado: (2019)

Real-Life Efficacy of Bevacizumab Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion according to Pro Re Nata or Treat-and-Extend Regimen in Eyes with or without Epiretinal Membrane
por: Hamam, Moustafa, et al.
Publicado: (2022)

Quo natas, Danio?—Recent Progress in Modeling Cancer in Zebrafish
por: Kirchberger, Stefanie, et al.
Publicado: (2017)

Characterization of the Interactions between Cereal Flour and “Nata Puree” in Batter
por: Tokuyasu, Ken, et al.
Publicado: (2022)

Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw
por: Kim, Jin-Woo, et al.
Publicado: (2016)

Molecular Basis for Amino-Terminal Acetylation by the Heterodimeric NatA Complex
por: Liszczak, Glen, et al.
Publicado: (2013)

Panel Doctors and Prescription Writing
Publicado: (1913)

Cannot write session to /tmp/vufind_sessions/sess_4n5ijlhkn816189ee5bfc3ohdc